STOCK TITAN

Revolution Medicines (NASDAQ: RVMD) director plans August stock sale after June $1.6M trade

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) received a notice that Mark A. Goldsmith, identified as a director or officer, plans to sell 80,000 shares of common stock under Rule 144. The planned sale is dated 08/21/2026, via Morgan Stanley Smith Barney LLC Executive Financial Services, and is tied to the exercise of stock options for cash. The securities information lists an aggregate market value of approximately $16,938,800.00 for these 80,000 shares, with 214,336,418 RVMD common shares outstanding. In the prior three months, Goldsmith reported selling 10,020 shares of common stock on 06/16/2026 for proceeds of $1,564,310.38.

Positive

  • None.

Negative

  • None.
Planned shares to be sold 80,000 shares Common stock sale under Rule 144 planned for 08/21/2026
Aggregate market value of planned sale $16,938,800.00 Value associated with 80,000 shares of RVMD common stock
Shares outstanding 214,336,418 shares RVMD common shares outstanding referenced in the notice
Shares sold in past 3 months 10,020 shares Sale by Mark A. Goldsmith on 06/16/2026
Proceeds from prior sale $1,564,310.38 Total proceeds from 10,020 RVMD shares sold on 06/16/2026
Planned sale date 08/21/2026 Date of intended Rule 144 sale and option exercise
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Exercise of Stock Options financial
"Common | 08/21/2026 | Exercise of Stock Options | Issuer"
Executive Financial Services financial
"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

FAQ

What does the Form 144 filing for RVMD disclose about Mark A. Goldsmith?

It discloses that Mark A. Goldsmith, a director or officer, has notified an intent to sell 80,000 shares of Revolution Medicines, Inc. common stock on 08/21/2026 under Rule 144, in connection with the exercise of stock options for cash.

How many RVMD shares does Mark A. Goldsmith plan to sell and when?

Mark A. Goldsmith plans to sell 80,000 shares of Revolution Medicines, Inc. common stock on 08/21/2026. The sale is indicated as being made pursuant to an exercise of stock options for cash.

What is the approximate market value of the RVMD shares covered by this Form 144?

The filing lists an aggregate market value of about $16,938,800.00 for the 80,000 shares of Revolution Medicines, Inc. common stock referenced in the planned Rule 144 sale.

How many Revolution Medicines (RVMD) shares are outstanding as referenced in this notice?

The Form 144 states that there are 214,336,418 shares of Revolution Medicines, Inc. common stock outstanding, as context for the planned Rule 144 sale by Mark A. Goldsmith.

What RVMD stock sales has Mark A. Goldsmith made in the last three months?

The filing reports that Mark A. Goldsmith sold 10,020 shares of Revolution Medicines, Inc. common stock on 06/16/2026, with total proceeds of $1,564,310.38, during the three months prior to the new planned sale.

Which broker is handling the planned RVMD share sale under Form 144?

The planned sale of 80,000 RVMD shares is listed through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature